Therapeutic Update in Idiopathic Pulmonary Fibrosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1007/s12016-010-8244-9.pdf
Reference48 articles.
1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304
2. American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664
3. Collard HR (2010) The age of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181:771–772
4. Michaelson JE, Aguayo SM, Roman J (2000) Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management. Chest 118:788–794
5. du Bois RM (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9:129–140
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel pirfenidone derivatives: synthesis and biological evaluation;RSC Medicinal Chemistry;2023
2. Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases;Current Pharmaceutical Design;2021-09-15
3. Integrated analysis of the molecular mechanisms in idiopathic pulmonary fibrosis;International Journal of Medical Sciences;2021
4. The roles of exosomal miRNAs and lncRNAs in lung diseases;Signal Transduction and Targeted Therapy;2019-11-13
5. Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival;Respiratory Investigation;2019-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3